Prospective Grant of Exclusive License: Development of Ocular Therapeutics Utilizing the Peptide C16Y and Related Peptides, 26304 [2012-10636]
Download as PDF
<![CDATA[
26304
Federal Register / Vol. 77, No. 86 / Thursday, May 3, 2012 / Notices
including taxicabs, hotel, and airport shuttles
will be inspected before being allowed on
campus. Visitors will be asked to show one
form of identification (for example, a
government-issued photo ID, driver’s license,
or passport) and to state the purpose of their
visit. Information is also available on the
Institute’s/Center’s home page: https://
deainfo.nci.nih.gov/advisory/ctac/ctac.htm,
where an agenda and any additional
information for the meeting will be posted
when available.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.392, Cancer Construction;
93.393, Cancer Cause and Prevention
Research; 93.394, Cancer Detection and
Diagnosis Research; 93.395, Cancer
Treatment Research; 93.396, Cancer Biology
Research; 93.397, Cancer Centers Support;
93.398, Cancer Research Manpower; 93.399,
Cancer Control, National Institutes of Health,
HHS)
Dated: April 27, 2012.
Jennifer S. Spaeth,
Director, Office of Federal Advisory
Committee Policy.
[FR Doc. 2012–10699 Filed 5–2–12; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Prospective Grant of Exclusive
License: Development of Ocular
Therapeutics Utilizing the Peptide
C16Y and Related Peptides
National Institutes of Health,
Public Health Service, HHS.
ACTION: Notice.
AGENCY:
Patent application number
Country
wreier-aviles on DSK7SPTVN1PROD with NOTICES
PCT/US2004/04142 ..................................................................................
10/588,884 ................................................................................................
2004317159 ..............................................................................................
2,555,792 ..................................................................................................
04 710659.6 ..............................................................................................
The patent rights in these inventions
have been assigned to the United States
of America.
The prospective exclusive license
territory may be ‘‘worldwide’’, and the
field of use may be limited to ‘‘use of
C16Y and related peptides in the
treatment of ocular disease.’’
DATES: Only written comments and/or
applications for a license which are
received by the NIH Office of
Technology Transfer on or before May
18, 2012 will be considered.
FOR FURTHER INFORMATION CONTACT:
Requests for copies of the patent
application(s), inquiries, AND
comments relating to the contemplated
exclusive license should be directed to:
Susan S. Rucker, JD, CLP, Senior
Advisor for Intellectual Property
Transactions, Office of Technology
Transfer, National Institutes of Health,
6011 Executive Boulevard, Suite 325,
Rockville, MD 20852–3804; Telephone:
(301) 435–4478; Facsimile: (301) 402–
0220; Email: ruckersu@mail.nih.gov.
SUPPLEMENTARY INFORMATION: The
technology encompassed by the patents
and/or patent applications (IP) to be
included in this exclusive license
relates to a protein designated C16Y and
variations thereof. C16Y is an
engineered peptide derived from
laminin gamma 1 chain having antiangiogenic properties. The C16Y
peptide is at least 5-fold more potent
VerDate Mar<15>2010
15:32 May 02, 2012
Jkt 226001
PCT
US
AU
CA
EP
Filing date or
international
filing date
02/12/2004
08/09/2006
02/12/2004
2/12/2004
2/12/2004
than the previously described C16S
peptide and has been shown to inhibit
choroidal neovascularization (CNV) in
vivo and inhibit angiogenesis in a tumor
bearing mouse model (see Ponce, et al
Cancer Research 63: 5060–64 (2003)).
The IP covers various C16Y
compositions and uses thereof,
particularly its use in treating ocular
diseases.
The prospective start up exclusive
license will be royalty bearing and will
comply with the terms and conditions
of 35 U.S.C. 209 and 37 CFR 404.7. The
prospective start up exclusive license
may be granted unless within fifteen
(15) days from the date of this published
notice, the NIH receives written
evidence and argument that establishes
that the grant of the license would not
be consistent with the requirements of
35 U.S.C. 209 and 37 CFR 404.7.
Only applications for a license in the
field of use set forth in this notice and
filed in response to this notice will be
treated as objections to the grant of the
contemplated start up exclusive license.
Comments and objections submitted to
this notice will not be made available
for public inspection and, to the extent
permitted by law, will not be released
under the Freedom of Information Act,
5 U.S.C. 552.
PO 00000
Frm 00064
Fmt 4703
Sfmt 4703
This is notice, in accordance
with 35 U.S.C. 209(c)(1) and 37 CFR
part 404.7(a)(1)(i), that the National
Institutes of Health, Department of
Health and Human Services, is
contemplating the grant of an exclusive
patent license to ODIN Biotech, a Texas
corporation, having a place of business
in Dallas, Texas, to practice the
inventions embodied in the patents and
patent applications belonging to the
patent family having HHS Reference
Number E–008–2004/0. The exclusive
license is one which qualifies under the
Start-Up License Agreement program
which is in place from October 1, 2011
through September 30, 2012. Specific
details regarding the individual patents
or patent applications which belong to
this patent family are set forth in the
table below:
SUMMARY:
Status
Expired ...............
Issued .................
Issued .................
Pending ..............
Pending ..............
Publication or patent
number
WO 2005/087250
8,039,585 B2
2004317159 B2
2555792 A1
1737479 A1
Dated: April 27, 2012.
Richard U. Rodriguez,
Director, Division of Technology Development
and Transfer, Office of Technology Transfer,
National Institutes of Health.
[FR Doc. 2012–10636 Filed 5–2–12; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HOUSING AND
URBAN DEVELOPMENT
[Docket Number FR–5623–N–01]
Federal Housing Administration (FHA)
Healthcare Facility Documents:
Proposed Revisions and Updates and
Notice of Information Collection
Office of the Assistant
Secretary for Housing—Federal Housing
Commissioner, HUD.
ACTION: Notice.
AGENCY:
Consistent with the
Paperwork Reduction Act of 1995
(PRA), HUD is publishing for public
comment a comprehensive set of closing
and other documents used in
connection with transactions involving
healthcare facilities (excluding
hospitals) that are insured pursuant to
section 232 of the National Housing Act
(Section 232). In addition to meeting
PRA requirements, this notice seeks
public comment for the purpose of
enlisting input from the lending
SUMMARY:
E:\FR\FM\03MYN1.SGM
03MYN1
]]>Agencies
[Federal Register Volume 77, Number 86 (Thursday, May 3, 2012)]
[Notices]
[Page 26304]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2012-10636]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
Prospective Grant of Exclusive License: Development of Ocular
Therapeutics Utilizing the Peptide C16Y and Related Peptides
AGENCY: National Institutes of Health, Public Health Service, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: This is notice, in accordance with 35 U.S.C. 209(c)(1) and 37
CFR part 404.7(a)(1)(i), that the National Institutes of Health,
Department of Health and Human Services, is contemplating the grant of
an exclusive patent license to ODIN Biotech, a Texas corporation,
having a place of business in Dallas, Texas, to practice the inventions
embodied in the patents and patent applications belonging to the patent
family having HHS Reference Number E-008-2004/0. The exclusive license
is one which qualifies under the Start-Up License Agreement program
which is in place from October 1, 2011 through September 30, 2012.
Specific details regarding the individual patents or patent
applications which belong to this patent family are set forth in the
table below:
----------------------------------------------------------------------------------------------------------------
Filing date or
Patent application number Country international Status Publication or patent number
filing date
----------------------------------------------------------------------------------------------------------------
PCT/US2004/04142............... PCT 02/12/2004 Expired........... WO 2005/087250
10/588,884..................... US 08/09/2006 Issued............ 8,039,585 B2
2004317159..................... AU 02/12/2004 Issued............ 2004317159 B2
2,555,792...................... CA 2/12/2004 Pending........... 2555792 A1
04 710659.6.................... EP 2/12/2004 Pending........... 1737479 A1
----------------------------------------------------------------------------------------------------------------
The patent rights in these inventions have been assigned to the
United States of America.
The prospective exclusive license territory may be ``worldwide'',
and the field of use may be limited to ``use of C16Y and related
peptides in the treatment of ocular disease.''
DATES: Only written comments and/or applications for a license which
are received by the NIH Office of Technology Transfer on or before May
18, 2012 will be considered.
FOR FURTHER INFORMATION CONTACT: Requests for copies of the patent
application(s), inquiries, AND comments relating to the contemplated
exclusive license should be directed to: Susan S. Rucker, JD, CLP,
Senior Advisor for Intellectual Property Transactions, Office of
Technology Transfer, National Institutes of Health, 6011 Executive
Boulevard, Suite 325, Rockville, MD 20852-3804; Telephone: (301) 435-
4478; Facsimile: (301) 402-0220; Email: ruckersu@mail.nih.gov.
SUPPLEMENTARY INFORMATION: The technology encompassed by the patents
and/or patent applications (IP) to be included in this exclusive
license relates to a protein designated C16Y and variations thereof.
C16Y is an engineered peptide derived from laminin gamma 1 chain having
anti-angiogenic properties. The C16Y peptide is at least 5-fold more
potent than the previously described C16S peptide and has been shown to
inhibit choroidal neovascularization (CNV) in vivo and inhibit
angiogenesis in a tumor bearing mouse model (see Ponce, et al Cancer
Research 63: 5060-64 (2003)). The IP covers various C16Y compositions
and uses thereof, particularly its use in treating ocular diseases.
The prospective start up exclusive license will be royalty bearing
and will comply with the terms and conditions of 35 U.S.C. 209 and 37
CFR 404.7. The prospective start up exclusive license may be granted
unless within fifteen (15) days from the date of this published notice,
the NIH receives written evidence and argument that establishes that
the grant of the license would not be consistent with the requirements
of 35 U.S.C. 209 and 37 CFR 404.7.
Only applications for a license in the field of use set forth in
this notice and filed in response to this notice will be treated as
objections to the grant of the contemplated start up exclusive license.
Comments and objections submitted to this notice will not be made
available for public inspection and, to the extent permitted by law,
will not be released under the Freedom of Information Act, 5 U.S.C.
552.
Dated: April 27, 2012.
Richard U. Rodriguez,
Director, Division of Technology Development and Transfer, Office of
Technology Transfer, National Institutes of Health.
[FR Doc. 2012-10636 Filed 5-2-12; 8:45 am]
BILLING CODE 4140-01-P
